Medical Management of Brain Metastases from Lung Cancer

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer

“…Thus, corticosteroids and WBRT remain the standard of care for patients with multiple BMs [1,2]. Approximately 60% of patients clinically respond to such therapy, but it is unclear if responses are due to WBRT and/or corticosteroids [2] With median overall survival (OS) under 4 months [4], improvements are needed.…”